Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

mRNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman Cut Its Rating on MRNA Earlier this month, Moderna reduced its 2025 ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

There are two common versions of codon charts, or codon tables. One is a square or rectangle, and the other is a circle. A ...

Investors should watch significant overhead areas on Moderna's chart around $57, $72, and $85, while also monitoring important support levels near $44 and $37. Moderna (MRNA) shares soared Tuesday as ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. Watch these crucial price levels.

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines ...